Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT06450418

Digital App for Speech & Health Monitoring

Digital App for Speech & Health Monitoring — Recruiting • Neurology • NCT06450418.

📅 10 Sep 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06450418
Sponsor
University of Edinburgh
Start
2024-07-12
ClinicaliQ Trial Snapshot
  • Digital App for Speech & Health Monitoring — Recruiting • Neurology • NCT06450418.
  • Sponsor: University of Edinburgh.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Many people living with neurodegenerative conditions like dementia, motor neuron disease (MND), multiple sclerosis (MS), and Parkinson's disease (PD), suffer from speech problems. Using common digital technologies such as smartphone apps, the investigators can record and analyse speech in detail to provide new information for people living with these conditions, researchers, and healthcare professionals. This study will investigate the use of these digital speech recordings to help diagnose and monitor these conditions. To take part, participants will have either a diagnosis of dementia, motor neuron disease, Parkinson's disease or Multiple…

Eligibility Snapshot
  • - Any one of the following: * A person with a diagnosis of Motor Neuron Disease, Dementia, Multiple Sclerosis, or Parkinson's Disease. * A relative or carer of the above who does not report to have a neurological condition. * A healthy volunteer who does not report to have a neurological condition.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)
Neurology · 07 May 2026
Oxybutynin is effective for neurogenic detrusor overactivity in patients aged 6+ years with spinal cord injury or spina bifida—consider as first-line antimuscarinic…
View guideline →
Clinical Brief
Former nurse dies amid dementia drug shortages
Neurology · BBC Health · 02 Sep 2026
Dementia medication shortages are affecting patient care and outcomes, with documented cases of treatment interruptions leading to clinical deterioration Family advocacy and…
View brief →
Clinical Brief
AI may speed up search for drugs to treat brain conditions
Neurology · BBC Health · 22 May 2026
AI tools are being developed to accelerate drug discovery for neurological conditions including motor neurone disease, potentially reducing development timelines This approach…
View brief →
Clinical Brief
New hope for children with severe epilepsy
Neurology · BBC Health · 30 Mar 2026
Researchers says millions of people globally could be carriers of the faulty gene behind the disorder. This update is most useful for…
View brief →
Clinical Brief
Families hit by long waits for dementia diagnosis
Neurology · BBC Health · 02 Sep 2026
Dementia diagnosis delays are widespread, with patients experiencing waits of months to years, creating prolonged uncertainty for families during a critical period…
View brief →
Guideline
Atogepant for treating migraine
Neurology · 30 Jun 2026
Atogepant is recommended as a preventive treatment option for episodic migraine in adults; consider initiating in patients with ≥4 migraine days per…
View guideline →